Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Bortezomib with Docetaxel and Cisplatin in Early Stage NSCLC
NCT00313690Phase 2Withdrawn
- Sponsor
- University of Southern California
- Start
- Apr 2006
- Modality
- Small Molecules, Modified Peptides
01
Overview
A Phase 2 trial of bortezomib in non-small cell lung cancer (NSCLC), sponsored by University of Southern California. Planned start Apr 2006; status: withdrawn.
02
Drugs
bortezomib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00313690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00313690.